GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Island Pharmaceuticals Ltd (ASX:ILA) » Definitions » Net-Net Working Capital

Island Pharmaceuticals (ASX:ILA) Net-Net Working Capital : A$0.02 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Island Pharmaceuticals Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Island Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Dec. 2024 was A$0.02.

The industry rank for Island Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:

ASX:ILA's Price-to-Net-Net-Working-Capital is ranked worse than
79.28% of 859 companies
in the Biotechnology industry
Industry Median: 3.98 vs ASX:ILA: 10.75

Island Pharmaceuticals Net-Net Working Capital Historical Data

The historical data trend for Island Pharmaceuticals's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Island Pharmaceuticals Net-Net Working Capital Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Net-Net Working Capital
0.07 0.05 0.02 -

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only 0.03 0.02 - - 0.02

Competitive Comparison of Island Pharmaceuticals's Net-Net Working Capital

For the Biotechnology subindustry, Island Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Island Pharmaceuticals's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.


;
;

Island Pharmaceuticals Net-Net Working Capital Calculation

Island Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2024 is calculated as

Net-Net Working Capital(A: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.66+0.75 * 0+0.5 * 0-1.046
-0-0)/126.767
=0.00

Island Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2024 is calculated as

Net-Net Working Capital(Q: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.992+0.75 * 0.14+0.5 * 0-0.42
-0-0)/181.597
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Island Pharmaceuticals  (ASX:ILA) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Island Pharmaceuticals Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Island Pharmaceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Island Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections. Its drug candidate ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and another mosquito (or vector) borne diseases. The company carries out its research and development activities principally in the geographic regions of Australia and the United States of America.

Island Pharmaceuticals Headlines

No Headlines